[go: up one dir, main page]

AR058194A1 - DRUGS THAT INCLUDE AN ANTIMUSCARINIC AGENT AND A CORTICOESTEROID - Google Patents

DRUGS THAT INCLUDE AN ANTIMUSCARINIC AGENT AND A CORTICOESTEROID

Info

Publication number
AR058194A1
AR058194A1 ARP060105053A ARP060105053A AR058194A1 AR 058194 A1 AR058194 A1 AR 058194A1 AR P060105053 A ARP060105053 A AR P060105053A AR P060105053 A ARP060105053 A AR P060105053A AR 058194 A1 AR058194 A1 AR 058194A1
Authority
AR
Argentina
Prior art keywords
corticoesteroid
drugs
antimuscarinic agent
medicament
inflammatory
Prior art date
Application number
ARP060105053A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR058194A1 publication Critical patent/AR058194A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Un medicamento que comprende, en forma separada o en conjunto, (A) una sal de glicopirronio y (B) furoato de mometasona, para administracion simultánea, secuencial o separada en el tratamiento de una enfermedad inflamatoria u obstructiva de las vías respiratorias.Claim 1: A medicament comprising, separately or together, (A) a glycopyrronium salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive respiratory tract disease .

ARP060105053A 2005-11-21 2006-11-17 DRUGS THAT INCLUDE AN ANTIMUSCARINIC AGENT AND A CORTICOESTEROID AR058194A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0523653.4A GB0523653D0 (en) 2005-11-21 2005-11-21 Organic compounds

Publications (1)

Publication Number Publication Date
AR058194A1 true AR058194A1 (en) 2008-01-23

Family

ID=35580402

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105053A AR058194A1 (en) 2005-11-21 2006-11-17 DRUGS THAT INCLUDE AN ANTIMUSCARINIC AGENT AND A CORTICOESTEROID

Country Status (14)

Country Link
US (1) US20080317862A1 (en)
EP (1) EP1954266A1 (en)
JP (1) JP2009516662A (en)
KR (1) KR20080069196A (en)
CN (1) CN101312721A (en)
AR (1) AR058194A1 (en)
AU (1) AU2006314723A1 (en)
BR (1) BRPI0618807A2 (en)
CA (1) CA2630224A1 (en)
GB (1) GB0523653D0 (en)
PE (1) PE20071081A1 (en)
RU (1) RU2008124825A (en)
TW (1) TW200803840A (en)
WO (1) WO2007057222A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP3106149B1 (en) 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CA2785349C (en) 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
RS53391B2 (en) 2009-12-23 2023-09-29 Chiesi Farm Spa Combination therapy for copd
RU2013142268A (en) 2011-02-17 2015-03-27 Сипла Лимитед PHARMACEUTICAL COMPOSITION
FR2987266B1 (en) * 2012-02-28 2014-12-19 Debregeas Et Associes Pharma PROCESS FOR OBTAINING A PHARMACEUTICAL COMPOSITION BASED ON MODAFINIL, PHARMACEUTICAL COMPOSITION THUS OBTAINED AND ITS APPLICATION
CN110403922A (en) 2013-01-28 2019-11-05 理森制药股份公司 Methods of treating autoimmune, respiratory and/or inflammatory disorders by inhalation of roflumilast N-oxide
CA2902795C (en) 2013-02-28 2021-06-15 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
BR112015022784B1 (en) 2013-03-15 2023-02-14 Pearl Therapeutics, Inc MICRONIZED CRYSTALLINE MATERIAL CONDITIONING METHOD AND CONDITIONING SYSTEMS
WO2015008205A2 (en) * 2013-07-13 2015-01-22 Mahesh Kandula Compositions and methods for the treatment of respiratory diseases
DK3089735T3 (en) 2013-12-30 2018-09-17 Chiesi Farm Spa STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
BR112017003888B1 (en) 2014-09-09 2022-11-16 Vectura Limited METHOD OF MANUFACTURING A DRY POWDER FORMULATION
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
CA3152578A1 (en) 2019-12-02 2021-06-10 Enrico Zambelli Stainles steel can for pressurised metered dose inhalers
CN117679423A (en) 2022-09-05 2024-03-12 立生医药(苏州)有限公司 Inhaled pharmaceutical compositions for preventing or treating respiratory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0057401B1 (en) * 1981-02-02 1984-08-01 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
AU2002210575A1 (en) * 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
WO2005074918A1 (en) * 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
WO2005074983A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
MX2007012084A (en) * 2005-03-30 2007-11-21 Schering Corp Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist.

Also Published As

Publication number Publication date
CN101312721A (en) 2008-11-26
BRPI0618807A2 (en) 2011-09-13
US20080317862A1 (en) 2008-12-25
AU2006314723A1 (en) 2007-05-24
RU2008124825A (en) 2009-12-27
WO2007057222A1 (en) 2007-05-24
PE20071081A1 (en) 2007-12-11
JP2009516662A (en) 2009-04-23
EP1954266A1 (en) 2008-08-13
KR20080069196A (en) 2008-07-25
CA2630224A1 (en) 2007-05-24
GB0523653D0 (en) 2005-12-28
TW200803840A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
AR058194A1 (en) DRUGS THAT INCLUDE AN ANTIMUSCARINIC AGENT AND A CORTICOESTEROID
CL2004001170A1 (en) INHALABLE PHARMACEUTICAL COMBINATION CONTAINING (A) FORMOTEROL, OR A SALT, OR A SOLVATE OF IT OR THE SALT AND (B) MOMETASONE FUROATE; PHARMACEUTICAL CASE THAT UNDERSTANDS IT; AND ITS USE IN THE THERAPY OF AN INFLAMMATORY OR OBSTRUCTIVE DISEASE OF THE V
CL2007002526A1 (en) A MEDICINAL PRODUCT THAT INCLUDES, SEPARATE OR TOGETHER: A) A GLYCOPIRRON SALT; B) A BETA-2 ADRENO-RECEIVER AGONIST SELECTED FROM SALMETEROL AND FORMOTEROL; AND C) A CORTICOSTEROID; PHARMACEUTICAL KIT; AND USE IN THE TREATMENT OF AN INFL DISEASE
ID29181A (en) COMBINATION OF FORMOTEROL AND TIOTROPIUM SALT
AR053026A1 (en) COMPOSITIONS OF ANTIBODIES ANTI FACTOR OF STIMULATION OF COLONIES OF MACROFAGOS (ANTI-M CSF)
BRPI0507966A (en) use of meloxicam for the treatment of respiratory diseases in pigs
AR022609A1 (en) COMBINATIONS OF A BETA-2 AGONIST AND A STEROID
BRPI0814957A2 (en) COMPOUND, PRODUCT, PHARMACEUTICAL AGENT, METHOD FOR PROPHYLAXY OR TREATMENT OF A DISEASE, DISORDER OR CONDITION, AND USE OF THE COMPOUND.
IL189500A (en) 5-substituted- pyrimidine-2,4-diamimes, pharmaceutical compositions comprising them and their use in the manufacture of a medicament for treatment of p2x3 and p2x2/3 recepror mediated disease
AR065392A1 (en) METHODS FOR TREATMENT BY INHALATION OF A DISEASE OR RESPIRATORY STATE
CY1106430T1 (en) MEDICATIONS FOR INHALATION CONTAINING VITAMINS AND AN ANTICHOLINEPG
JP2007536277A5 (en)
CR7152A (en) A PDE4 INHIBITOR AND A COMBINATION ANTI-POLINERGIC AGENT TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS.
BRPI0807285A2 (en) "COMPOSITION, METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION, UNIT FORM OF DOSAGE, METHOD FOR ADMINISTRATING A BIOLOGICAL ACTIVE AGENT NEEDING THE AGENT, METHOD FOR INCREASING BIODISPONABILITY FOR PREPARING AN AGENT OF COMPOSITION"
ATE494889T1 (en) PHARMACEUTICAL COMBINATION WITH 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL AND PARACETAMOL
ATE513562T1 (en) NON-SPECIFIC IMMUNO-STIMULANT AGENTS
CL2007002875A1 (en) Pharmaceutical composition covered by a film comprising capecitabine and at least one disintegrant, useful in the treatment of cancer for patients who have difficulty swallowing oral solid dosage forms.
MX2009011900A (en) Diabetic wound healing.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
ECSP078014A (en) DOSAGE REGIME FOR PRASUGREL
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
AR057904A1 (en) MEDICATIONS THAT INCLUDE AN ANTIMUSCERINIC AGENT AND A CORTICOESTEROID
AR054253A1 (en) ASSOCIATION BETWEEN RAILWAY AND AN ARTEMISININE DERIVATIVE FOR THE TREATMENT OF PALUDISM
CL2008000965A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN OPIACEAL ANALGESIC, AND ITS USE FOR PAIN TREATMENT.
UY27564A1 (en) PHARMACEUTICAL COMBINATION

Legal Events

Date Code Title Description
FA Abandonment or withdrawal